Last updated: February 23, 2026
What is the Drug NDC 49884-0277?
NDC 49884-0277 refers to Emtricitabine and Tenofovir Alafenamide (F/TAF) 200/25 mg. It is marketed under the brand name Descovy, used in the treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP).
Market Size and Demand Drivers
Current Market Landscape
- Global HIV Treatment Market (2023): Valued at approximately $24 billion, with a compound annual growth rate (CAGR) of 6.5% projected through 2028.
- U.S. Market Share: Represents roughly 60% of global revenues. Descovy’s share is estimated at 15% within the PrEP segment and 8% within overall HIV therapeutics.
Key Demand Drivers
- Pre-Exposure Prophylaxis (PrEP): Increased awareness and insurance coverage have expanded PrEP use. CDC reports approximately 1.2 million U.S. individuals on PrEP in 2022, with steady growth.
- HIV Treatment: Greater diagnosis rates, improved adherence, and expanding coverage in low- and middle-income countries.
- Patent Status: Patents expiring in 2026, opening markets for generics.
Competitive Landscape
| Drug Name |
Active Ingredient |
Market Share (2022) |
Price (per pill) |
Patent Expiry |
| Descovy |
Emtricitabine/Tenofovir Alafenamide |
15% (PrEP segment) |
$30 - $35 |
2026 |
| Truvada |
Emtricitabine/Tenofovir Disoproxil Fumarate |
40% |
$25 – $30 |
2020 (generic) |
| Apretude |
Cabotegravir (long-acting injectable) |
10% |
$3,500 (per injection) |
2030 |
Source: IQVIA data, 2022; CDC reports
Price Projections
Short-Term (2023–2025)
- Brand Price Stability: Around $30 per pill in the U.S., influenced by manufacturing costs and negotiated pricing with payers.
- Generic Entry Impact: Starting as early as 2026, generics could reduce prices by 50% or more, leading to per-pill prices near $12–$15.
- Market Dynamics: Insurers may seek discounts for branded Descovy before generics introduce price competition.
Mid- to Long-Term (2026–2030)
- Generics Market Entry: Expected to catalyze price declines in developed markets.
- Price Estimates: Per-pill prices could decrease to $10–$15, driven by increased competition and manufacturing scale.
- Market Penetration: Generic availability will expand access, especially in emerging markets, potentially increasing total volume while reducing unit revenues.
Revenue Impact Estimates
| Year |
Estimated Revenue (U.S.) |
Notes |
| 2023 |
$300 million |
Stable pricing, steady demand |
| 2024 |
$320 million |
Slight growth, increased awareness |
| 2025 |
$330 million |
Pre-patent expiry impact begins |
| 2026 |
$200 million |
Patent expiry, generic entry |
| 2027 |
$150 million |
Market penetration of generics |
(Assumes volume growth offsets price decline initially, then gradual decrease post-patent expiry)
Strategic Considerations
- Patent Litigation and Patent Term Extensions: Potential for patent challenges or extensions could delay generic competition.
- Pricing Strategies: Branded manufacturers may implement tiered pricing or discount programs pre-patent expiry.
- Market Expansion: Emergence in developing countries where HIV treatment budgets are increasing.
Key Takeaways
- NDC 49884-0277 (Descovy) operates primarily in HIV PrEP and treatment in the U.S. and globally.
- Revenue is projected to be around $300–330 million in the near term.
- Price is stable at approximately $30 per pill prior to 2026, with a sharp decline anticipated post-patent expiry due to generics.
- Long-term price reduction to $10–$15 per pill could substantially expand access, especially in emerging markets.
FAQs
1. When will generics enter the market for NDC 49884-0277?
Generic versions are expected around 2026, following patent expiration or legal extension.
2. How could patent disputes impact market entry?
Patent challenges or litigation delays could postpone generic availability by 1–2 years, maintaining higher prices temporarily.
3. What are the primary factors influencing Descovy’s pricing?
Manufacturing costs, payer negotiations, patent status, and competition are significant factors.
4. What is the potential market size in emerging markets?
Estimated at over 10 million HIV-positive individuals and at-risk populations, with access expanding post-generic entry.
5. Are there alternative treatments impacting Descovy’s market?
Yes. Long-acting injectables like Apretude and other oral regimens have gained market share, influencing revenue projections.
Sources
[1] IQVIA. (2022). National Prescription Audit.
[2] CDC. (2022). HIV Surveillance Data.
[3] MarketWatch. (2023). Global HIV Drugs Market Report.
[4] FDA. (2022). Patent listings and expirations.
